NOVO — Juli 2025
-
Så er der Cagrisema, kliniske data i dette område er ren markedsføring, gode data, best in Class = federe markedsføring. Her fejler studiet da det teknisk blev sat forkert op og data kommer dårligere ud end forventet og guidet. Nyt forsøg i gang, men først efter længere tavshed, igen på bagkant.
-
Analytiker: Valget af ny Novo Nordisk-topchef kan have ført til yderligere aktietæsk
- Jeg havde forventet, at der blev valgt en ekstern kandidat, siger aktieanalytiker.
DR (www.dr.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind